Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry | Zendy

Christos Papadopoulos | Zendy; Ilias K. Gartzonikas | Zendy; Tatiani K Pappa | Zendy; Theodora E. Markatseli | Zendy; Michael P Migkos | Zendy; Paraskevi V. Voulgari | Zendy; Alexandros A. Drosos | Zendy

Open Access

Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry

Author(s) -

Christos Papadopoulos,

Ilias K. Gartzonikas,

Tatiani K Pappa,

Theodora E. Markatseli,

Michael P Migkos,

Paraskevi V. Voulgari,

Alexandros A. Drosos

Publication year - 2019

Publication title -

rheumatology advances in practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 4

ISSN - 2514-1775

DOI - 10.1093/rap/rkz007

Subject(s) - medicine , adalimumab , etanercept , infliximab , discontinuation , rheumatoid arthritis , arthritis , tumor necrosis factor alpha , gastroenterology , surgery

TNF-α inhibitors establish an effective therapeutic option in RA showing an acceptable safety profile. Infections and allergic reactions appear more often with infliximab, while serious infections did not differ among them. RA patients treated with infliximab are more likely to discontinue treatment earlier compared with the other alternatives.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research